- Home
- ACRS vs UNB Comparison
ACRS vs UNB Comparison
Compare ACRS & UNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- UNB
- Stock Information
- Founded
- ACRS 2012
- UNB 1891
- Country
- ACRS United States
- UNB United States
- Employees
- ACRS N/A
- UNB N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- UNB Major Banks
- Sector
- ACRS Health Care
- UNB Finance
- Exchange
- ACRS Nasdaq
- UNB Nasdaq
- Market Cap
- ACRS 132.0M
- UNB 135.8M
- IPO Year
- ACRS 2015
- UNB 1998
- Fundamental
- Price
- ACRS $4.32
- UNB $31.40
- Analyst Decision
- ACRS Buy
- UNB
- Analyst Count
- ACRS 6
- UNB 0
- Target Price
- ACRS $7.20
- UNB N/A
- AVG Volume (30 Days)
- ACRS 6.0M
- UNB 7.7K
- Earning Date
- ACRS 11-06-2024
- UNB 01-15-2025
- Dividend Yield
- ACRS N/A
- UNB 4.58%
- EPS Growth
- ACRS N/A
- UNB N/A
- EPS
- ACRS N/A
- UNB 1.93
- Revenue
- ACRS $27,079,000.00
- UNB $46,385,000.00
- Revenue This Year
- ACRS N/A
- UNB N/A
- Revenue Next Year
- ACRS N/A
- UNB N/A
- P/E Ratio
- ACRS N/A
- UNB $16.21
- Revenue Growth
- ACRS 26.35
- UNB N/A
- 52 Week Low
- ACRS $0.77
- UNB $21.00
- 52 Week High
- ACRS $5.17
- UNB $32.00
- Technical
- Relative Strength Index (RSI)
- ACRS 74.71
- UNB 70.86
- Support Level
- ACRS $3.67
- UNB $29.98
- Resistance Level
- ACRS $5.17
- UNB $31.22
- Average True Range (ATR)
- ACRS 0.47
- UNB 0.86
- MACD
- ACRS 0.20
- UNB 0.07
- Stochastic Oscillator
- ACRS 72.93
- UNB 99.07
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group. Geographically, all the business activity is functioned through the United States.